What is Brief History of Hisun Pharmaceutical Company?

What is the history of Hisun Pharmaceutical?

Founded in 1956, Hisun Pharmaceutical began as a chemical enterprise in Taizhou, China. Its mission was to become an internationally respected pharmaceutical company through innovation for human benefit.

From its early days, the company has grown into a major integrated pharmaceutical enterprise, covering research, production, and marketing. It has played a significant role in addressing health crises, including its contributions during the COVID-19 epidemic in 2020.

Hisun Pharmaceutical is recognized for its substantial output of active pharmaceutical ingredients and finished products. In 2021, it was noted as one of China's largest producers of antibiotics and anti-tumor drugs. The company reported an operating income of CN¥9.787 billion for the full year 2024, with a net profit of CN¥601.2 million. For the first quarter of 2025, revenue reached CN¥2.63 billion. As of July 24, 2025, its market capitalization was around $2 billion, reflecting its evolution into a key global pharmaceutical entity.

The Hisun Pharmaceutical company origins trace back to 1956 in Taizhou, China. Initially established as a chemical enterprise, its trajectory shifted significantly in the early 1970s when it strategically ventured into the pharmaceutical sector, marking a crucial turning point in its history.

Hisun Pharmaceutical Company Origins

The Hisun Pharmaceutical company was founded in 1956, evolving from a chemical enterprise to a dedicated pharmaceutical player. Its mission has always been focused on innovation for human benefit, aiming for global recognition.

• Established in 1956 in Taizhou, China.
• Diversified into pharmaceuticals in the early 1970s.
• Early focus on Active Pharmaceutical Ingredients (APIs) and finished products.
• Became a state-owned listed company in 2000.

The initial business model of Hisun Pharma background centered on the research, development, production, and sale of APIs, later expanding to finished pharmaceutical products. The company's foundational mission was to 'persist in pharmaceutical innovation for the benefit of human beings,' with a vision to become a 'widely respected international pharmaceutical company.' This commitment guided its early product development and market strategies. A significant milestone in the Hisun Pharmaceutical timeline occurred in 2000 when it became a state-owned listed company, issuing A-shares and entering the stock market. Understanding the Revenue Streams & Business Model of Hisun Pharmaceutical provides further insight into its operational evolution.

The Hisun Pharmaceutical company's journey began in the early 1970s, evolving from a chemical enterprise into a focused pharmaceutical entity. This transformation laid the groundwork for its future expansion and specialization in drug substances and preparations, marking the start of its significant Hisun Pharma background.

Transition to Pharmaceutical Focus

In its initial phase, Hisun Pharmaceutical transitioned from a chemical enterprise to a dedicated pharmaceutical company in the early 1970s. This period was crucial for building its expertise in drug substances and preparations, setting the stage for its future growth.

Public Listing and Capital Infusion

A pivotal moment in the Hisun Pharmaceutical timeline was its listing on the Shanghai Stock Exchange in 2000, establishing it as a state-owned listed company. This event provided essential capital and enhanced visibility, fueling subsequent expansion efforts.

Portfolio Diversification and R&D Expansion

The company's product portfolio expanded to cover diverse therapeutic areas, with a particular emphasis on anti-infectives and anti-tumor drugs, which continue to be areas of strength. Major R&D sites were established in Beijing and Shanghai, complementing its Taizhou headquarters.

Global Market Entry and Strategic Alliances

Hisun Pharmaceuticals USA, Inc. was founded in 2009 to penetrate the US market. Today, 80% of its API income comes from overseas, with APIs exported to over 70 countries. A significant joint venture with Pfizer was formed in 2012, aiming to develop and commercialize branded generics, reflecting its commitment to Mission, Vision & Core Values of Hisun Pharmaceutical.

The Hisun Pharmaceutical company has a rich history marked by significant milestones and a strong commitment to innovation. With a robust portfolio spanning innovative drugs, biological drugs, generics, and high-end APIs across therapeutic areas like anti-tumor and cardiovascular disorders, the company consistently invests over 8% of its annual revenue in R&D. This dedication has resulted in more than 100 patents in over 30 countries and recognition through 47 national key projects, including two second-class state technological invention awards. Explore the Brief History of Hisun Pharmaceutical to understand its journey.

Hisun Pharmaceutical's innovation is evident in its diverse product development and strategic expansion into advanced biomanufacturing. The company's R&D expenditure, exceeding 8% of annual revenue, fuels the creation of a broad spectrum of pharmaceutical products. This focus on cutting-edge research has led to significant achievements in areas like cholesterol treatment with its product Sesme.

Innovative Drug Development

Hisun Pharmaceutical has developed a robust portfolio of innovative drugs, biological drugs, and generic drugs. This includes treatments for anti-tumor, anti-infection, cardiovascular, and endocrine disorders.

High-End API Production

The company is a significant producer of high-end active pharmaceutical ingredients (APIs), contributing to the global pharmaceutical supply chain.

Biomanufacturing Expansion

The establishment of Yansheng Synthetics in July 2025 signifies a strategic move into high-end biomanufacturing, showcasing a forward-looking approach to industry trends.

Cholesterol Treatment Advancement

The significant sales growth of its key product Sesme in 2024 highlights its leading position and innovation in the cholesterol treatment market.

Insulin Product Launch

The launch of Insulin Aspart Injection (Hisaining) in May 2025 demonstrates the company's ongoing commitment to expanding its therapeutic offerings.

R&D Investment and Patents

Consistent investment in R&D, with over 8% of annual revenue allocated, has resulted in over 100 patents granted in more than 30 countries.

Despite its successes, Hisun Pharmaceutical has navigated financial challenges, including revenue declines in recent years. The company experienced a net loss of CN¥93.17 million in fiscal year 2023, but successfully pivoted to a net profit of CN¥601.18 million in fiscal year 2024.

Revenue Fluctuations

The company saw a 5.7% decrease in revenue in 2024 compared to 2023, and a 3.4% decrease in Q1 2025 compared to Q1 2024, indicating market pressures.

Financial Turnaround

A significant challenge was the net loss in 2023, but this was overcome by achieving a net profit of CN¥601.18 million in 2024, demonstrating resilience.

Market Adaptation

Responding to market dynamics, Hisun has strategically focused on its integrated API-Drug Product business and expanded into biomanufacturing, showcasing adaptability.

Overcoming Financial Hurdles

The company's ability to transition from a net loss to a substantial net profit highlights improved management efficiency and optimized resource allocation.

Navigating Industry Trends

The company's strategic pivots and focus on global collaboration are key to maintaining its competitive edge in the evolving pharmaceutical landscape.

Maintaining Innovation Focus

Despite financial challenges, Hisun Pharmaceutical has consistently maintained its focus on innovation and R&D, a core strength throughout its history.

The Hisun Pharmaceutical company history is marked by significant growth and strategic shifts, beginning with its founding in Taizhou, China, in 1956. The company's evolution into the pharmaceutical field accelerated in the early 1970s. A major milestone was its listing on the Shanghai Stock Exchange in 2000, establishing it as a state-owned listed entity. The Hisun Pharma background includes expansion into biological pharmaceuticals in 2003 and international growth with the establishment of Hisun Pharmaceuticals USA, Inc. in 2009. Key developments include a joint venture with Pfizer in 2012, though Pfizer later divested its stake in 2017. The company's biologics division saw a significant change in 2019 when PAG acquired control of Hisun BioRay. Hisun Pharmaceutical received recognition for its contributions during the COVID-19 epidemic in 2020.

Financial Performance and Growth Projections

In March 2025, Hisun Pharmaceutical reported a net profit of CN¥601.2 million for the full year 2024, marking a significant turnaround from the previous year. The company's Q1 2025 revenue reached CN¥2.63 billion. Revenue is forecast to grow by an average of 1.9% annually over the next two years.

Strategic Focus on Synthetic Biology

Hisun is strategically prioritizing high-end biomanufacturing and aims to become a leader in synthetic biology in China. This includes establishing Yansheng Synthetics in July 2025 and signing a cooperation agreement with Nanjing Normal University for synthetic biology research.

Pipeline Expansion and Product Launches

The company is actively expanding its pipeline with new development candidates in oncology, central nervous system (CNS), and cardiovascular therapeutic areas. Hisun launched its insulin product, Insulin Aspart Injection (Hisaining), in May 2025, with three bone-related products set for launch in August 2025.

Commitment to Innovation and Global Standards

Hisun Pharmaceutical's future direction is guided by its mission of 'persisting in pharmaceutical innovation for the benefit of human beings'. The company's strong research and development capabilities and adherence to international quality standards position it well to address future industry trends and challenges, building on its Competitors Landscape of Hisun Pharmaceutical.